{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:22:59Z","timestamp":1726759379262},"reference-count":127,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T00:00:00Z","timestamp":1297296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The most frequent kidney disease associated with chronic hepatitis C virus (HCV) infection is membranoproliferative glomerulonephritis in patients with type II mixed cryoglobulinaemia. The principal clinical manifestations of glomerular disease in HCV\u2010infected patients are the presence of proteinuria and haematuria with or without impaired kidney function. Pharmaceutical regimens vary because the main pathogenesis of renal dysfunction often mediated by cryoglobulins has not been fully elucidated. HCV infection remains common in patients on renal replacement therapy and has an adverse impact on their survival. Safe and effective pharmaceutical regimens have not been yet established and nosocomial spread within dialysis units continues to occur. Monotherapy with interferon for HCV infection is probably more effective in dialysis than in non\u2010uraemic patients, while experience with ribavirin is limited because of its adverse haemolytic effect. Based on shortage of cadaver kidneys and the fact that HCV renal transplant recipients have better survival than stay on maintenance haemodialysis or at list for transplantation, health organization proposed the use of cadaver kidneys from anti\u2010HCV\u2010positive donors, bringing up concerns and conflicting views. This present review describes the main renal manifestations of HCV infection, the epidemiological and clinical characteristics of chronic kidney disease population and comments on the limitations and shortcomings of current therapeutical regiments.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2011.02458.x","type":"journal-article","created":{"date-parts":[[2011,2,17]],"date-time":"2011-02-17T13:38:16Z","timestamp":1297949896000},"page":"1071-1080","source":"Crossref","is-referenced-by-count":19,"title":["Hepatitis C virus and kidney: a strong association with different clinical aspects"],"prefix":"10.1111","volume":"31","author":[{"given":"Chrisoula","family":"Pipili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Ilonidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450107"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200301000-00015"},{"key":"e_1_2_6_4_2","first-page":"1147","article-title":"American Association for the Study of Liver Diseases","volume":"39","author":"Strader DB","year":"2004","journal-title":"diagnosis, management, and treatment of hepatitis C"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302183280703"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.V62220","article-title":"Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan","volume":"6","author":"Yamabe H","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_7_2","first-page":"8","article-title":"Mixed cryoglobulinemia","volume":"39","author":"Dammacco F","year":"2007","journal-title":"a model of virus-related disease in internal medicine"},{"key":"e_1_2_6_8_2","first-page":"44","article-title":"Antibody to hepatitis c virus increases with on hemodialysis","volume":"38","author":"Hardy NM","year":"1992","journal-title":"Clin Nephrol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000168462"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1170-0"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1681\/ASN.V52186","article-title":"Epidemiology of hepatitis C virus infection in patients with renal disease","volume":"5","author":"Garcia\u2010Valdecasas J","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000142"},{"key":"e_1_2_6_13_2","first-page":"813","article-title":"Therapy of hepatitis C virus\u2010associated glomerulonephritis","volume":"21","author":"Fabrizi F","year":"2008","journal-title":"current approaches"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.247"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328333ba5d"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.19.2101"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03710708"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.78"},{"key":"e_1_2_6_20_2","first-page":"735","article-title":"Brief communication","volume":"144","author":"McGuire BM","year":"2006","journal-title":"glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.37.836"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.471"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000045243"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1159\/000187372"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90020-2"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1681\/ASN.V9122244","article-title":"Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy","volume":"9","author":"Markowitz GS","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_27_2","first-page":"212","article-title":"Interferon therapy for HCV\u2010associated glomerulonephritis","volume":"30","author":"Fabrizi F","year":"2007","journal-title":"meta-analysis of controlled trials"},{"key":"e_1_2_6_28_2","first-page":"842","article-title":"Rituximab treatment for glomerulonephritis in HCV\u2010associated mixed cryoglobulinemia","volume":"45","author":"Quartuccio L","year":"2006","journal-title":"efficacy and safety in absence of steroids"},{"key":"e_1_2_6_29_2","first-page":"283","article-title":"Anti\u2010CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis","volume":"67","author":"Cacoub P","year":"2008","journal-title":"where do we stand?"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.09.009"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/BOR.0b013e3282f1330c","article-title":"Treatment of hepatitis C\u2010associated mixed cryoglobulinemia vasculitis","volume":"20","author":"Saadoun D","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"e_1_2_6_32_2","first-page":"1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"109","author":"KDIGO.","year":"2008","journal-title":"Kidney Int"},{"key":"e_1_2_6_33_2","first-page":"1335","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C","volume":"9","author":"Ghany MG","year":"2009","journal-title":"an update"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.11.020"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.094508"},{"key":"e_1_2_6_36_2","first-page":"51","article-title":"HCV\u2010related cryoglobulinemic glomerulonephritis","volume":"78","author":"Garini G","year":"2007","journal-title":"implications of antiviral and immunosuppressive therapies"},{"key":"e_1_2_6_37_2","first-page":"775","article-title":"Effect of antiviral therapy on hepatitis C virus related glomerulopathy","volume":"19","author":"Abbas G","year":"2008","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/08860220802595906"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-010-0282-3"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10699"},{"key":"e_1_2_6_41_2","first-page":"3696","article-title":"Antiviral therapy for hepatitis C virus\u2010associated mixed cryoglobulinemia vasculitis","volume":"54","author":"Saadoun D","year":"2006","journal-title":"a long-term follow up study"},{"key":"e_1_2_6_42_2","first-page":"628","article-title":"Hepatitis C in hemodialysis patients","volume":"28","author":"Rahnavardi M","year":"2008","journal-title":"current global magnitude, natural history, diagnostic difficulties, and preventive measures"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2006.3111"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.09.021"},{"key":"e_1_2_6_45_2","first-page":"81","article-title":"HCV\u2010RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis","volume":"34","author":"Rigopoulou EI","year":"2005","journal-title":"results from five hemodialysis units in central Greece"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34613"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2002.00368.x"},{"key":"e_1_2_6_48_2","first-page":"700","article-title":"Hepatitis C virus infection in Jordanian haemodialysis units","volume":"51","author":"Bdour S.","year":"2002","journal-title":"serological diagnosis and genotyping"},{"key":"e_1_2_6_49_2","first-page":"107","article-title":"The impact of polymerase chain reaction assays for the detection of hepatitis C virus infection in a hemodialysis unit","volume":"18","author":"Hussein MM","year":"2007","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"e_1_2_6_50_2","first-page":"128","article-title":"The prevalence of hepatitis C virus antibodies among hemodialysis patients in Jeddah area, Saudi Arabia","volume":"6","author":"Al\u2010Shohaib SS","year":"1995","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006070736"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1086\/502058"},{"key":"e_1_2_6_53_2","first-page":"101","article-title":"Hepatitis C virus infection in hemodialysis patients in Sudan","volume":"18","author":"El\u2010Amin HH","year":"2007","journal-title":"two centers' report"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2003.07.001"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762005000500003"},{"key":"e_1_2_6_56_2","first-page":"2335","article-title":"Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents","volume":"65","author":"Fissell RB","year":"2004","journal-title":"the DOPPS"},{"key":"e_1_2_6_57_2","first-page":"1343","article-title":"High prevalence of hepatitis C virus (HCV) DNA in dialysis patients","volume":"168","author":"Bukh J","year":"1993","journal-title":"failure of commercially available antibody tests to identify a significant number of patients with HCV infection"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91397-5"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139880903200502"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40101198.x"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200004150-00045"},{"key":"e_1_2_6_62_2","first-page":"2221","article-title":"Liver damage in hemodialysis patients with hepatitis C virus viremia","volume":"45","author":"Furusyo N","year":"2000","journal-title":"a prospective 10-year study"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2005.09.010"},{"key":"e_1_2_6_64_2","first-page":"151","article-title":"High ALT levels predict viremia in anti\u2010HCV\u2010positive HD patients if a modified normal range of ALT is applied","volume":"54","author":"Espinosa M","year":"2000","journal-title":"Clin Nephrol"},{"key":"e_1_2_6_65_2","first-page":"1","article-title":"Centers for disease control and prevention","volume":"47","author":"Centers for Disease Control and Prevention.","year":"1998","journal-title":"recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease"},{"key":"e_1_2_6_66_2","first-page":"1","article-title":"Centers for disease control and prevention","volume":"50","author":"Centers for Disease Control and Prevention.","year":"2001","journal-title":"recommendations for preventing transmission of infections among chronic hemodialysis patients"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801293380503"},{"key":"e_1_2_6_68_2","first-page":"122","article-title":"Co\u2010infection by hepatitis B virus and hepatitis C virus in renal transplantation","volume":"10","author":"Pouteil\u2010Noble C","year":"1995","journal-title":"morbidity and mortality in 1098 patients"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)00825-2"},{"key":"e_1_2_6_70_2","first-page":"1","article-title":"Impact of hemodialysis therapy on hepatitis C virus infection","volume":"32","author":"Fabrizi F","year":"2009","journal-title":"a deeper insight"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.00788.x"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200208000-00013"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.51938.x"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.RVI.0000109403.52762.C4"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.565"},{"key":"e_1_2_6_76_2","first-page":"1","article-title":"FibroTest and FibroScan for the prediction of hepatitis C\u2010related fibrosis","volume":"102","author":"Shaheen AA","year":"2007","journal-title":"a systematic review of diagnostic test accuracy"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000183399.85804.02"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1159\/000320751"},{"key":"e_1_2_6_79_2","first-page":"191","article-title":"Hepatitis C in chronic kidney disease","volume":"27","author":"Lemos LB","year":"2007","journal-title":"predialysis patients present more severe histological liver injury than hemodialysis patients?"},{"key":"e_1_2_6_80_2","first-page":"428","article-title":"Quantitative assessment of HCV load in chronic hemodialysis patients","volume":"80","author":"Fabrizi F","year":"1998","journal-title":"a cross-sectional survey"},{"key":"e_1_2_6_81_2","first-page":"2286","article-title":"Hemodialysis prevents liver disease caused by hepatitis C virus","volume":"56","author":"Rampino T","year":"1999","journal-title":"role of hepatocyte growth factor"},{"key":"e_1_2_6_82_2","first-page":"143","article-title":"Changes in viremia and circulating interferon\u2010alpha during hemodialysis in hepatitis C virus\u2010positive patients","volume":"42","author":"Badalamenti S","year":"2003","journal-title":"only coincidental phenomena?"},{"key":"e_1_2_6_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.12.003"},{"key":"e_1_2_6_84_2","first-page":"697","article-title":"The impact of hepatitis C virus infection on survival in dialysis patients","volume":"14","author":"Fabrizi F","year":"2007","journal-title":"meta-analysis of observational studies"},{"key":"e_1_2_6_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi231"},{"key":"e_1_2_6_86_2","first-page":"119","article-title":"Interferon\u2010alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients","volume":"19","author":"Rocha CM","year":"2007","journal-title":"efficacy and tolerance"},{"key":"e_1_2_6_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.07.013"},{"key":"e_1_2_6_88_2","first-page":"16","article-title":"Monotherapy with peginterferon alpha\u20102b {12\u2003kDa} for chronic hepatitis C infection in patients undergoing haemodialysis","volume":"28","author":"Amarapurkar DN","year":"2007","journal-title":"Trop Gastroenterol"},{"key":"e_1_2_6_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2006.00662.x"},{"key":"e_1_2_6_90_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP67366"},{"key":"e_1_2_6_91_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.165076"},{"key":"e_1_2_6_92_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-008-7134-z"},{"key":"e_1_2_6_93_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.255"},{"key":"e_1_2_6_94_2","doi-asserted-by":"publisher","DOI":"10.1080\/08860220701813368"},{"key":"e_1_2_6_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21050"},{"key":"e_1_2_6_96_2","doi-asserted-by":"publisher","DOI":"10.1080\/08860220701641579"},{"key":"e_1_2_6_97_2","article-title":"Pegylated interferon alpha\u20102a for treatment of chronic HCV infection in hemodialysis patients","author":"Alsaran K","year":"2011","journal-title":"a single Saudi center experience"},{"key":"e_1_2_6_98_2","first-page":"768","article-title":"Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients","volume":"82","author":"Fabrizi F","year":"2010","journal-title":"meta-analysis of clinical trials"},{"key":"e_1_2_6_99_2","first-page":"79","article-title":"Interferon monotherapy of chronic hepatitis C in dialysis patients","volume":"15","author":"Fabrizi F","year":"2008","journal-title":"meta-analysis of clinical trials"},{"key":"e_1_2_6_100_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01850309"},{"key":"e_1_2_6_101_2","doi-asserted-by":"publisher","DOI":"10.1086\/655682"},{"key":"e_1_2_6_102_2","first-page":"1213","article-title":"Short\u2010term interferon\u2010alfa therapy for acute hepatitis C","volume":"39","author":"Nomura H","year":"2004","journal-title":"a randomized controlled trial"},{"key":"e_1_2_6_103_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000079613.81511.3C"},{"key":"e_1_2_6_104_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.01025.x"},{"key":"e_1_2_6_105_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.139"},{"key":"e_1_2_6_106_2","first-page":"133","article-title":"Interferon therapy in hemodialysis patients with chronic hepatitis C","volume":"100","author":"Mahmoud IM","year":"2005","journal-title":"study of tolerance, efficacy and post transplantation course"},{"key":"e_1_2_6_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.12.109"},{"key":"e_1_2_6_108_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000128911.87538.AA"},{"key":"e_1_2_6_109_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2004.00606.x"},{"key":"e_1_2_6_110_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199510000-00007"},{"key":"e_1_2_6_111_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199603270-00007"},{"key":"e_1_2_6_112_2","first-page":"1254","article-title":"Hepatitis C virus\u2010associated fibrosing cholestatic hepatitis after renal transplantation","volume":"66","author":"Toth CM","year":"1998","journal-title":"response to interferon-alpha therapy"},{"key":"e_1_2_6_113_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.29"},{"issue":"2","key":"e_1_2_6_114_2","first-page":"1466","article-title":"Impact of pretransplant hepatitis C antibody status upon long\u2010term patient and renal allograft survival \u2013 A 5\u2010 and 10\u2010year follow\u2010up","volume":"25","author":"Ynares C","year":"1993","journal-title":"Transplantation Proc"},{"key":"e_1_2_6_115_2","first-page":"1452","article-title":"Hepatitis C virus antibody status and survival after renal transplantation","volume":"5","author":"Fabrizi F","year":"2005","journal-title":"meta-analysis of observational studies"},{"key":"e_1_2_6_116_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00883.x"},{"key":"e_1_2_6_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90345-0"},{"key":"e_1_2_6_118_2","first-page":"853","article-title":"Hepatitis C virus infection and kidney transplantation","volume":"83","author":"Maluf DG","year":"2007","journal-title":"predictors of patient and graft survival"},{"key":"e_1_2_6_119_2","first-page":"129","article-title":"Severe evolution of chronic hepatitis C in renal transplantation","volume":"17","author":"Zylberberg H","year":"2002","journal-title":"a case control study"},{"key":"e_1_2_6_120_2","first-page":"3576","article-title":"Chronic hepatitis C infection in patients with end stage renal disease renal disease","volume":"94","author":"Sterling RK","year":"1999","journal-title":"characterization of liver histology and viral load in patients awaiting renal transplantation"},{"key":"e_1_2_6_121_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00918.x"},{"key":"e_1_2_6_122_2","first-page":"22","article-title":"Peginterferon alfa\u20102b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation","volume":"12","author":"Schmitz V","year":"2007","journal-title":"Ann Transplant"},{"key":"e_1_2_6_123_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200007270-00001"},{"key":"e_1_2_6_124_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.30113.x"},{"key":"e_1_2_6_125_2","first-page":"86","article-title":"Alpha\u2010interferon treatment of chronic hepatitis C","volume":"116","author":"Black M","year":"1992","journal-title":"need for accurate diagnosis in selecting patients"},{"key":"e_1_2_6_126_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000158279.29506.E0"},{"key":"e_1_2_6_127_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04082"},{"key":"e_1_2_6_128_2","first-page":"562","article-title":"Pegylated interferon\u2010alpha\u2010based treatment for chronic hepatitis C in renal transplant recipients","volume":"22","author":"Pageaux GP","year":"2009","journal-title":"an open pilot study"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2011.02458.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2011.02458.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:52:10Z","timestamp":1695495130000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2011.02458.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,10]]},"references-count":127,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1478-3231.2011.02458.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02458.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,10]]}}}